Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis.
about
Radiation dose effect in locally advanced non-small cell lung cancerChallenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy?Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directionsRetrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs)Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume.Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review.SBRT in operable early stage lung cancer patients.Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center SettingStereotactic radiotherapy for early stage non-small cell lung cancerA Survey of Stereotactic Body Radiotherapy in KoreaLungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspectiveStereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours.Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis.Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicityCompatibility of the repairable-conditionally repairable, multi-target and linear-quadratic models in converting hypofractionated radiation doses to single doses.Hypofractionated radiotherapy for medically inoperable stage I non-small cell lung cancer.Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain.The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.To gate or not to gate - dosimetric evaluation comparing Gated vs. ITV-based methodologies in stereotactic ablative body radiotherapy (SABR) treatment of lung cancer.Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer.Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer.Hypofractionated 3D radiotherapy for inoperable T1-3 N0-1 non-small-cell lung cancer.Guideline for radiotherapy with curative intent in patients with early-stage medically inoperable non-small-cell lung cancer.Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy.Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.Computed tomography fluoroscopy-guided percutaneous (125)I seed implantation for safe, effective and real-time monitoring radiotherapy of inoperable stage T1-3N0M0 non-small-cell lung cancer.Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity.Evaluation of ray tracing and Monte Carlo algorithms in dose calculation and clinical outcomes for robotic stereotactic body radiotherapy of lung cancers.Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer.A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical OnTreatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours.Lung tumor motion change during stereotactic body radiotherapy (SBRT): an evaluation using MRI.Investigating the impact of treatment delivery uncertainties on treatment effectiveness for lung SABR.Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives.Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directionsSingle dose partial breast irradiation using an MRI linear accelerator in the supine and prone treatment position
P2860
Q26823043-79F85A25-5D8A-48CD-A363-C8E86900C21DQ27301421-8C3C5CA7-0731-4FA4-ACBD-C9D7BC045B47Q28083924-DB6BF55E-CA85-483A-B116-8EB0D4C9763FQ28085744-26FFFD86-56D9-414A-9BB9-BB1E8151B873Q33571109-3028D79F-1CF3-4244-8398-87893D1094FAQ34366580-D0AD6255-8038-4249-BAC0-80E76BCA2677Q34667302-AF7F1D88-ED59-4D78-BF5E-E5DBA792C629Q35200592-8380A1F8-3621-4AB7-9485-483642647DD7Q35796322-A24A251C-CBF7-48D5-A60C-94AAEB9C07F8Q35824255-1A43690A-51EE-4D45-932F-D5CD08D4D650Q35862313-1E9842C9-302D-4BC0-9F13-E30C00A54B32Q36235727-C52B86BE-0CEE-4C86-939A-CB232A33BE3AQ36286591-D16AD2D1-3BF6-4538-AAE0-335CA392ECB2Q36382039-0F51FDA7-F318-4C45-9748-B5CF9B91FD9CQ36524133-1327996A-BAE5-48DF-9D2C-1E8A3057D668Q36550532-85776242-AB73-4421-B313-E4294A909318Q36661372-3171118E-2505-4B55-BCED-F8AE4A7FA934Q36840379-EF9842C8-2770-42FC-B66E-6A7FCA9D40D1Q36949855-E1034CF1-6B31-445D-8171-12DEF247A9EEQ37178916-64FDEC4C-247C-47B7-82D3-E67BB9987093Q37278431-8F4627A8-040C-4F75-AC0A-ABA2517CCA37Q37468265-811C11FF-0857-4A10-B481-1D35EFE0D126Q37566614-B17CE649-9F9D-4587-ADAD-17CD4231E271Q37601085-02E85B3C-5FBD-4DCB-A712-66E4A7E3DBCEQ37672027-8D9B22BD-70FB-4A5E-B88D-45DD71164E9EQ38685007-8DBE3919-6D72-4800-B4F4-E26D484053B5Q38849150-E43C57DD-62DA-4BD1-A0A2-B0ABB919B768Q39015830-1B990F61-6079-4523-91CE-777207ADC707Q40141235-D0B9D88F-A45E-4C20-8E75-FB17D95A9952Q41920328-4EBA00F6-62F4-46D2-B7DE-06E77842D5E6Q44020055-57C08D0D-3A02-447E-8B34-3298AF03D33DQ47097838-370DE846-76C5-4746-8933-1D0657C9D5FDQ47149089-A0996D18-D829-4B59-9ACE-030F1D0DDD4BQ48015363-0EC3CCF3-E41F-49E1-A2C5-A3D65C6194DDQ50863889-EF7768AC-1FD1-4492-890A-156995DB58E4Q51719448-9CE82637-7C8A-4102-B4A6-D56225104587Q52855374-EA1EB137-62AA-43A3-9CC8-26AA383CC118Q55282076-9AD1B766-A59F-489C-B27D-6AA6942007C0Q57177641-0817F6A8-FB8E-4D25-BDA6-9AFDC35FC7B5Q58555997-8C0C04E8-544E-40C4-91B5-BECA1CCBF19C
P2860
Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Which is the optimal biologica ...... lung cancer? A meta-analysis.
@ast
Which is the optimal biologica ...... lung cancer? A meta-analysis.
@en
type
label
Which is the optimal biologica ...... lung cancer? A meta-analysis.
@ast
Which is the optimal biologica ...... lung cancer? A meta-analysis.
@en
prefLabel
Which is the optimal biologica ...... lung cancer? A meta-analysis.
@ast
Which is the optimal biologica ...... lung cancer? A meta-analysis.
@en
P2093
P1476
Which is the optimal biologica ...... lung cancer? A meta-analysis.
@en
P2093
Baosheng Li
Dongqing Wang
Fujun Yang
Hongsheng Li
Jian Zhang
P304
P356
10.1016/J.IJROBP.2011.04.034
P407
P577
2011-06-12T00:00:00Z